Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Shareholders Approve Genoptix Merger

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that its shareholders have approved its proposed merger with Genoptix.

Late last year, Genoptix agreed to acquire Rosetta for $10 million in cash, but the deal was scuttled after failing to garner enough support from Rosetta shareholders. Several months later, the companies signed a new merger agreement that valued Rosetta at $9 million.

Rosetta said that its shareholders have approved the latest agreement and that the merger is now slated to close on May 27. Following completion of the deal, Rosetta will become a privately held subsidiary of Genoptix, and its shares will cease to trade on the Nasdaq.

During midday trading, shares of Rosetta were down less than 1 percent to $.43.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more